* Abcellera Biologics Inc ABCL.OQ reported a quarterly
adjusted
loss of 11 cents per share for the quarter ended in June. The
mean expectation of eight analysts for the quarter was for a
loss of 13 cents per share.
* Revenue fell 78.1% to $10.06 million from a year ago;
analysts
expected $12.37 million.
* Abcellera Biologics Inc's reported EPS for the quarter was
a
loss of 11 cents.
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
* Abcellera Biologics Inc shares had risen by 7.4% this
quarter and lost 31.5% so far this year.
* The company reported a quarterly loss of $30.53 million.
* Wall Street's median 12-month price target for Abcellera
Biologics Inc is $27.50
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
This summary was machine generated from LSEG Refinitiv data
August 3 at 09:02 p.m. UTC. All figures in US dollars unless
otherwise stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2023 -0.13 -0.11 Beat
Mar. 31 2023 -0.14 -0.14 Met
Dec. 31 2022 -0.01 -0.10 Missed
Sep. 30 2022 0.05 0.08 Beat